Hot Investor Mandate 3: Taiwan-based CVC Investing in Therapeutics and Digital Health

22 Jun

A corporate venture of a publicly listed Taiwanese pharmaceutical company now focuses on strategic investments and add-on acquisition for its portfolio companies. Typical allocation size ranges from US$5-20 million. The firm is currently seeking opportunities in Asia and the US.

The CVC is investing strategically for its portfolio companies in select sectors. Within therapeutics, the firm considers small molecules, biologics, antibody-drug conjugates, and gene therapies in oncology. The firm also considers CNS, pain, cardiovascular and metabolic disease, and infectious diseases. The firm typically invests in late preclinical projects to phase 1 trial. Within medical technologies, the firm is interested in innovative digital health innovations.

The firm is looking for experienced management teams with strong scientific expertise and management skills. The firm typically requests a board seat in its portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: